Genflow launches new development program in ophtamology, advancing its cSIRT6

Genflow Biosciences, the only publicly listed longevity company in Europe, has launched a new development program in ophthalmology, focused on advancing a novel gene therapy leveraging its proprietary Centenarian SIRT6 (cSIRT6).

The company said that this therapy will utilize a specially designed non-viral vector engineered for precise delivery of Genflow’s SIRT6 to the eye.  The therapy is designed to combat ocular problems including several pathologies of the cornea and glaucoma, the company said.

This initiative is part of Genflow’s continued efforts to optimize its gene therapy and proprietary Centenarian SIRT6. As part of this effort, Genflow has signed a Material Transfer Agreement (MTA) with a leading ophthalmology company, to collaborate on the design and development of the eye-targeted cSIRT6 non-viral vector to target ocular diseases, Genflow said. These therapies will leverage Genflow’s proprietary SIRT6 Centenarian gene technology, in combination with an advanced vector delivery system, the company said.

Dr. Eric Leire, CEO of Genflow Biosciences, said: “We are thrilled to advance our ophthalmology program. The eye, as a closed and accessible compartment, presents an ideal target for gene therapy. More importantly, we believe that SIRT6 holds significant promise to transform the treatment landscape for corneal endothelial disorders and glaucoma.”